Two randomized phase III trials from Japan demonstrated that progression-free survival (PFS) with gefitinib was significantly longer than platinum-based chemotherapy as a first-line treatment in patients with advanced NSCLC who carried activating EGFR mutation [10,11]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.